




Minnesota Medical Cannabis Program

September 12, 2017

Office of Medical Cannabis

2014: MN became 22nd state with full medical cannabis program



Minnesota Medical Cannabis Program

- Minnesota Laws 2014, Chapter 311
 - Codified at Minn.Stat. §§152.22 to 152.37
- The main objectives of the law are:
 - Allowing the therapeutic use of medical cannabis, while
 - Preventing its misuse or diversion; and
 - Learning from patient experiences
- July 1, 2015 Medical cannabis distributed to enrolled patients

Minnesota's Program is Different From Most

- No smokeable or plant form marijuana (only liquids and oils in capsule, tincture, or vaporized form)
- Only two vertically-integrated manufacturers (cultivation-production-distribution supply chain)
- Commitment to learning from experience with program (reports and observational studies on effectiveness, side effects, etc.)
 - Patients agree to provide access to medical data

Patients – Requirements

- Must be **Minnesota resident** with qualifying medical condition
 - No program i.d. card
 - No reciprocity with other jurisdictions
- Must enroll in registry and agree that data in registry can be used for aggregate reports and research
- \$200 annual enrollment fee (\$50 reduced fee if receiving assistance)
- Cost of medical cannabis is out of pocket

Patients – Qualifying Medical Conditions

- **Cancer** or its treatment, with severe or chronic pain, or severe nausea, or severe wasting
- **Glaucoma**
- **HIV/AIDS**
- **Tourette’s Syndrome**
- **Amyotrophic Lateral Sclerosis** (ALS or Lou Gehrig’s Disease)
- **Seizures**, including those characteristic of epilepsy
- Severe and persistent **Muscle Spasms**, including those characteristic of multiple sclerosis
- **Inflammatory Bowel Disease**, including Crohn’s Disease
- **Terminal Illness** with life-expectancy < 1 year – with severe or chronic pain, or severe nausea, or severe wasting)
- ***Intractable Pain***
- ***PTSD***

Qualifying Medical Conditions (cont.)

- The law authorizes the Health Commissioner to add qualifying medical conditions
 - Process for citizens to petition MDH to add additional conditions. During 2016 petition window, 9 conditions petitioned – 1 added (PTSD)
 - 2017 – 10 conditions petitioned for consideration
- Legislature can add or remove qualifying conditions

Approved and Active Patients (as of Aug 31, 2017)

Total = 6,606

(8,454 including non-active)

By Qualifying Conditions:

- 67.6% Intractable pain
- 15.8% Severe and persistent muscle spasms
- 11.4% Cancer
- 6.0% Seizures
- 3.9% Inflammatory bowel disease
- 3.2% PTSD
- 1.4% Terminal illness
- 1.1% HIV/AIDS
- ≤ 1% each: Tourette syndrome; Glaucoma; ALS

Note: 11.6% of patients >1 condition


Age distribution:

0-4	(<1%)
5-17	(2%)
18-24	(3%)
25-35	(14%)
36-49	(26%)
50-64	(35%)
65+	(19%)

Gender: M/F

49%/51%

Patients Active in Registry (as of 8/31/17)



Health Care Practitioner – 968 registered with OMC

- Certify patient has qualifying medical condition (and annual recert.)
- Indicate whether patient needs caregiver to access/administer
- Acknowledge medical relationship with patient and sufficient knowledge of history, physical findings and test results to certify diagnosis; establish treatment plan; be available for ongoing care
- Agree to provide health record data at request of Commissioner
- Certifying providers may view their own patients' product purchases and use instructions, symptom scores, side effects

Medical Cannabis Manufacturers



LeafLine Labs

- Eagan
- St. Paul
- St. Cloud
- Hibbing




MinnMed

- Minneapolis
- Bloomington
- Rochester
- Moorhead



Office of Medical Cannabis

Overview of MN Medical Cannabis Program



*Care-giver may represent a patient by applying and meeting conditions including a background check.

Manufacturers – Products

- Manufacturers each determine their own product line
- Different medical cannabis products in MN are characterized by different ratios of THC:CBD and mode of delivery
- Products range from:
high CBD/low THC – 1:1 – low CBD/high THC
- Current products are listed on manufacturers' websites (links on OMC website)
- **Insurance does not cover cost of medical cannabis**



Independent Laboratory Testing

- Content – Cannabinoid Profile
- Contamination:
 - Metals
 - Pesticides
 - Microbials
 - Residual Solvents
- Consistency and Stability (3 month intervals)

- **Laboratory must be approved by MDH**



Manufacturers – Distribution Requirements

- At the manufacturers' distribution locations, a MN-licensed pharmacist is responsible for dispensing medical cannabis to the patients enrolled in the registry
- The pharmacist must consult with the patient and recommend the formulation and dosage of medical cannabis for the patient
- There is a maximum 30-day supply limit
- There are also packaging and labelling requirements

Program Research Functions

Sources of information:

- Reported data (self-evaluations)/transactions
- Opinion surveys of patient and their certifying health care practitioner
- Monthly and annual adverse event reporting
- Potential for focused studies incorporating medical record information

Learning from Participants' Experience – report

Report of observations from first year cohort was released this June

- Patients generally report a high degree of benefit, but varies by medical condition
- Health care providers report a lower degree of benefit, though still substantial
- Side effects are relatively uncommon and are mild to moderate in severity
- Affordability of the medical cannabis is an issue for most patients

For Additional Information

- Website:
 - [Http://www.health.state.mn.us/topics/cannabis/](http://www.health.state.mn.us/topics/cannabis/)
 - OR
 - [Http://mn.gov/medicalcannabis](http://mn.gov/medicalcannabis)
- Phone:
 - 651-201-5598
 - 844-879-3381
- Email:
 - Health.cannabis@state.mn.us

Thank you!